Coverage and future reimbursement (effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered ...

Right now, there's a 0 percent reduction cap in place for Medicare Part B users, which means patients don't have any upfront costs for these lab tests. But in a few weeks, the government plans to ...

Lucid Diagnostics offers asymmetric upside, with Medicare reimbursement as a near-term inflection point unlocking a $2–3M backlog. Read more on LUCD stock here.

If you've just celebrated your 65th birthday or it's coming up in the next year, your mailbox is probably full of postcards, flyers and letters about your eligibility for Medicare. Before you sign ...